• Contact
  • Press And News

Atopic Dermatitis

Trial 75:The study involved ten patients with atopic dermatitis who were administered particular strains of lactic yeasts. At the end of the study the patients treated with KLUYVER B0399 (Kluyveromyces fragilis B0399) obtained a normal range of total IgE.

Prof. A. Tulli – Director of the Clinic of Dermatology, University of Studies “G. d’Annunzio” Chieti (Italy)



Prof. A. Tulli – Director of the Clinic of Dermatology, University of Studies “G. d’Annunzio” Chieti (Italy)


The study was conducted on the basis of recent considerations on patients affected by atopic dermatitis. In about 80% of these patients a reduction in the efficiency of cellular immunity was observed, along with an elevated increase of total IgE. This could explain why atopic and non-atopic patients have a different distribution of subclasses of T lymphocytes. Given that T lymphocytes are divided into two types - Th1 cells which produce IL2 and IFN gamma and Th2 cells which produce interleucine IL 4,5,6 and 10 - and given that IFN gamma inhibits the IgE which are induced by the IL4, it was found that patients with atopic dermatitis had very low levels of IFN gamma and therefore a tendency toward a high level of IgE. This high level of IgE induces a hypersensitivity of the disease with critical consequences of the pathogenesis itself.


Ten (10) patients with atopic dermatitis and with high seric levels of IgE, between the ages of 6 and 10, were treated orally with capsules containing the active ingredient Kluyveromyces marxianus fragilis B0399 (typified lactic yeasts: KLUYVER B0399).
Dosage: 1 capsule a day for 30 days. During the treatment the normal specific therapies were also applied.
After 30 days the seric levels of the IgE of the patients were controlled and showed a normal range of total IgE .


The results obtained show that the administration of Kluyveromyces B0399 favors the therapeutic action. This oral therapy with exogenous microorganisms (lactic yeasts KLUYVER B0399) can be a valid aid and adjuvant in atopic dermatitis , with an improvement of the coenaesthesia of the patient.

2024. © All rights reserved. Laboratori Turval Italia srl (TURVAL Laboratories Ltd.) - Head Office and Research Dpt: Friuli innovazione (AREA international Science Park-TS), Via Linussio 51-33100 Udine (IT) – P. IVA 01883020305
We use cookies to enhance your browsing experience. If you want to disable cookies, please set your browser.